关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。

8 g0 y) u4 w* J1 h: Q作者：来自澳大利亚
来源：Haematologica. 2011.8.9.
  R8 |+ w8 o6 A% a, ]Dear Group,

, P0 ]5 D* D0 W/ T9 ?) ASome of you are on Dasatinib (Sprycel) and we wish to give news on all CML
' b0 m. V+ L8 u; S5 ytherapies. Here is a report from Australia on 3 patients who went off Sprycel
after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
# @8 o. V" c+ o) W+ R! C+ r1 Z) Premain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
! t/ A: g* R  S$ Pdoes spike up the immune system so I hope more reports come out on this issue.
5 L: T2 H4 D* m+ e
The remarkable news about Sprycel cessation is that all 3 patients had failed
Gleevec and Sprycel was their second TKI so they had resistant disease. This is
) S( k- B9 ~+ Ldifferent from the stopping Gleevec trial in France which only targets patients
who have done well on Gleevec.

Hopefully, the doctors will report on a larger study and long-term to see if the
response off Sprycel is sustained.

$ b1 X9 E: I* ^4 `Best Wishes,
' x0 S& W- b& r; I8 KAnjana
* c1 V, k( A& f7 O! ~% g

) A$ S& ]4 O6 `$ g# y
/ t+ Z* f6 r" a' xHaematologica. 2011 Aug 9. [Epub ahead of print]
4 K( ]* j$ M9 PDurable complete molecular remission of chronic myeloid leukemia following
dasatinib cessation, despite adverse disease features.
; K; k! f/ Z$ }. W. ~7 a# u  MRoss DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
Source
4 M& E9 o$ n0 m6 y& A2 oAdelaide, Australia;

& Z- R. t& T1 H0 b/ zAbstract
Patients with chronic myeloid leukemia, treated with imatinib, who have a
durable complete molecular response might remain in CMR after stopping
) {! t6 O) M- htreatment. Previous reports of patients stopping treatment in complete molecular
response have included only patients with a good response to imatinib. We
describe three patients with stable complete molecular response on dasatinib
% z" E5 r+ o& ?5 _) `3 gtreatment following imatinib failure. Two of the three patients remain in
complete molecular response more than 12 months after stopping dasatinib. In
these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
show that the leukemic clone remains detectable, as we have previously shown in
9 }. b; b6 q7 o( eimatinib-treated patients. Dasatinib-associated immunological phenomena, such as
, {$ Y" U+ F2 F8 @  A" B: u2 Pthe emergence of clonal T cell populations, were observed both in one patient
" t* }9 U% W" m2 l; }. Dwho relapsed and in one patient in remission. Our results suggest that the
  d* G) `; a0 ~characteristics of complete molecular response on dasatinib treatment may be
similar to that achieved with imatinib, at least in patients with adverse
disease features.
  ]* k# r& K6 S' Q% e; a1 k: }

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
9 s- [" t$ R5 z, t2 u: N" c    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
4 @  W  f/ L8 x' F    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。
' `0 u4 ]) l; F( |) o
& S7 l* R6 ~% N! {" [5 @( m! l: U作者：来自法国STIM试验
3 a4 w3 G9 B( v+ f6 ~  R; }来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事